Non-Alcoholic Steatohepatitis (NASH) Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 20 04:37 2022
Non-Alcoholic Steatohepatitis (NASH) Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Non-Alcoholic Steatohepatitis (NASH) Market
DelveInsight’s “Non-Alcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Alcoholic Steatohepatitis (NASH) Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

DelveInsight’s “Non-Alcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Alcoholic Steatohepatitis (NASH)  Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Some of the key facts of the Non-Alcoholic Steatohepatitis (NASH) Market Report:

  • A study of Estes et al. (2018), stated that there are varied estimates of NAFLD prevalence in the general population. An estimated 17%‐51% of adults have NAFLD. In the study, the prevalence of NASH was calculated based on previously published estimates and modeling of fibrosis progression. The study assumed that up to 5% of NAFLD cases without NASH could be NASH regressors, with most NASH regressors having no fibrosis (F0 stage). Therefore, a relatively small number of fibrotic cases (F1-F4) were classified as non-NASH NAFLD, and the vast majority of modeled fibrotic cases (F1-F4) were assumed to be NASH.
  • According to a study by Petta et al. (2019), NAFLD is one of the most frequent causes of chronic liver disease worldwide, affecting around 24% of the global population. In Italy, NAFLD prevalence ranges between 20%-30%. Nonalcoholic steatohepatitis (NASH) comprises nearly 25% of NAFLD patients 

Non-Alcoholic Steatohepatitis (NASH) Market Report Key Benefits:

  • In the coming years, the Nonalcoholic Steatohepatitis (NASH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Nonalcoholic Steatohepatitis (NASH) R&D. The therapies under development are focused on novel approaches to treat the disease condition   
  • Major players such as Intercept Pharmaceuticals, Enyo Pharma, 89 bio, Akero Therapeutics, Rivus Pharmaceuticals, Inc., and others are involved in developing therapies for Nonalcoholic Steatohepatitis (NASH). The launch of emerging therapies will significantly impact the Nonalcoholic Steatohepatitis (NASH) market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Nonalcoholic Steatohepatitis (NASH).

 

Got queries? Click here to know more about the Non-Alcoholic Steatohepatitis (NASH) Market Landscape.

Non-Alcoholic Steatohepatitis(NASH)Overview

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that encompasses the entire spectrum of fatty liver disease, from simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. It is a common chronic liver disease and is defined as liver inflammation and damage caused by the buildup of fat in the liver. Much like adults, children who have certain unhealthy conditions may also develop NAFLD and NASH.The exact cause of NAFLD is not known. The likely cause of developing NAFLD – either simple fatty liver or NASH – is in case of overweight or obesity, type 2 diabetes or pre-diabetes, abnormal levels of fats reported in blood, and others.

 Non-Alcoholic Steatohepatitis (NASH) Epidemiological Segmentation 

  • Non-Alcoholic SteatohepatitisTotal prevalent cases
  • Non-Alcoholic Total diagnostic cases
  • Non-Alcoholic Total gender-specific diagnosed prevalent cases
  • Non-Alcoholic Total severity specific diagnosed prevalent cases
  • Non-Alcoholic Treatable cases

Non-Alcoholic Steatohepatitis (NASH) Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-Alcoholic Steatohepatitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies. The report gives complete detail of the Non-Alcoholic Steatohepatitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market. According to DelveInsight, the Nonalcoholic Steatohepatitis (NASH) market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Non-Alcoholic Steatohepatitis (NASH) Market Landscape 

Non-Alcoholic Steatohepatitis (NASH) Market Drivers

  • Rich emerging pipeline
  • Increase in the patient pool

Non-Alcoholic Steatohepatitis (NASH) Market Barriers

  • No approved treatment
  • Under diagnoses and poor prognosis

Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market Assessment

As per DelveInsight, globally, several key companies are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Some of the emerging therapies are in the advanced stages of clinical development and are expected to hit the market in the coming years.

Key companies in the Non-Alcoholic Steatohepatitis (NASH) Market include:

  • Intercept Pharmaceuticals 
  • Enyo Pharma 
  • 89 bio
  • Akero Therapeutics, Inc 
  • Rivus Pharmaceuticals, Inc., and many others

Non-Alcoholic Steatohepatitis (NASH) Therapies Covered in the report include

  • Obeticholic acid (OCA) 
  • Vonafexor 
  • Pegozafermin 
  • Efruxifermin 
  • HU6 and many more

 Table of Contents

  • . Key Insights
  • . Report Introduction
  • . Executive Summary of Non-Alcoholic Steatohepatitis(NASH)
  •   Disease Background and Overview
  •   Epidemiology and patient population of EU 5 and United States 
  • . Non-Alcoholic Steatohepatitis(NASH) Emerging Therapies
  • . Non-Alcoholic Steatohepatitis(NASH) Market Outlook
  •  Market Access and Reimbursement of Therapies
  • . Market drivers
  •   Market barriers
  •   Appendix
  •   Non-Alcoholic Steatohepatitis(NASH) Report Methodology
  • . DelveInsight Capabilities
  • . Disclaimer
  • . About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/